INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501661-47-00

Acronym

INCB 39110-801

Enrollment

Registered

2023-05-11

Start date

2023-08-23

Completion date

Unknown

Last updated

2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelofibrosis ; postlung transplant (BOS); chronic graft-versus-host disease

Brief summary

Assessment of AEs and SAEs reported in participants continuing to receive itacitinib.

Interventions

DRUGItacitinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Assessment of AEs and SAEs reported in participants continuing to receive itacitinib.	—

Countries

Austria, Belgium, Germany, Greece, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026